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Abstract
Plasmodium vivax (Pv) is the second most important human malaria parasite. Recent data indicate that the impact of Pv
malaria on the health and economies of the developing world has been dramatically underestimated. Pv has a unique
feature in its life cycle. Uninucleate sporozoites (spz), after invasion of human hepatocytes, either proceed to develop into
tens of thousands of merozoites within the infected hepatocytes or remain as dormant forms called hypnozoites, which
cause relapses of malaria months to several years after the primary infection. Elimination of malaria caused by Pv will be
facilitated by developing a safe, highly effective drug that eliminates Pv liver stages, including hypnozoites. Identification
and development of such a drug would be facilitated by the development of a medium to high throughput assay for
screening drugs against Pv liver stages. We undertook the present pilot study to (1) assess the feasibility of producing large
quantities of purified, vialed, cryopreserved Pv sporozoites and (2) establish a system for culturing the liver stages of Pv in
order to assess the effects of drugs on the liver stages of Pv. We used primaquine (PQ) to establish this assay model, because
PQ is the only licensed drug known to clear all Pv hepatocyte stages, including hypnozoites, and the effect of PQ on Pv
hepatocyte stage development in vitro has not previously been reported. We report that we have established the capacity
to reproducibly infect hepatoma cells with purified, cyropreserved Pv spz from the same lot, quantitate the primary
outcome variable of infected hepatoma cells and demonstrate the inhibitory activity of primaquine on the infected
hepatoma cells. We have also identified small parasite forms that may be hypnozoites. These data provide the foundation
for finalizing a medium throughput, high content assay to identify new drugs for the elimination of all Pv liver stages.
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Introduction
Plasmodium vivax (Pv) is the second most important malaria
parasite, which infects humans. Recent data indicate that the
impact of Pv malaria on the health and economies of the
developing world has been dramatically underestimated [1,2]. The
number of clinical cases globally due to Pv infection has been
estimated to be between 80–300 million per year [3] out of 250–
500 million total estimated clinical malaria cases per year caused
by all human malaria parasites [4]. Although Pv infection is
believed to cause benign disease in comparison to infection caused
by P. falciparum, some recent studies reported severe symptoms and
signs, including death, due to Pv infection [5,6]. It is also reported
that severe symptoms in Pv infection may be due to the infection
with multidrug resistant parasites [7,8].
Pv has a unique feature in its life cycle. Uninucleate sporozoites
(spz), after invasion of human hepatocytes, either proceed to
develop into tens of thousands of merozoites within the infected
hepatocytes or remain for a long time as dormant hypnozoites
[9,10]. The factors, which lead invaded spz in the hepatocytes to
take the hypnozoite route, are not known. The primary attack of
Pv malaria generally occurs within 10–20 days of exposure to spz-
infected mosquitoes. However, activation of hypnozoites after the
primary attack causes additional blood stage infections called
relapses. Some studies have suggested that the parasites causing
relapses are clonally identical to the parasites causing the first
primary attack [11,12]. However, more recently, studies using
microsatellite markers identified from the Pv genome sequence
showed that relapse infections often result from activation of
heterologous hypnozoites [13,14]. Regardless, for successful
control of Pv, complete clearance of hypnozoites is required. At
present due to non-existence of any precise biomarker, distinction
between hypnozoites and mere slow growing liver stage parasites is
not defined at all. Primaquine is the only drug currently available
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nothing is known about its mechanism of action. Primaquine can
cause severe hemolytic toxicity in glucose 6-phosphate dehydro-
genase (G6PD) deficient subjects and thus screening for G6PD
deficiency must be done before administration. Also, as the G6PD
status of the unborn fetus cannot be determined easily, primaquine
is not prescribed to pregnant women infected with Pv. Tafeno-
quine, which is an 8 aminoquinoline with a much longer half-life
than primaquine is under development [16], but has the same
toxicity in G6PD-deficient individuals. Furthermore, unless
primaquine is taken with food, it causes significant gastrointestinal
disturbance. Therefore, there is an urgent need to develop more
drugs, which could effectively control infection by Pv. One of the
obstacles to develop effective drugs against Pv pre-erythrocyte
stages is the lack of standardized, medium to high throughput
hepatocyte based assay platforms or any small animal model of Pv
spz infection. Pv hepatocyte stages can be produced in vitro by
infecting monolayers of primary human hepatocytes [17], HepG2-
A16 human hepatoma cells [18], and HC-04 human hepatocytes
[19]. It has been quite difficult to reproducibly use these cell
culture based platforms for screening new drugs against liver
stages, because it has been difficult to obtain adequate quantities of
Pv spz, and each time Pv spz are obtained they are from a different
strain of Pv or a different infection of non-human primates with
the same strain, in other words, a different lot of Pv spz.
At Sanaria Inc., we are developing an attenuated P. falciparum
whole spz vaccine, the PfSPZ Vaccine. In order to manufacture
the PfSPZ Vaccine we have developed methods for aseptic
production of P. falciparum gametocytes and Anopheles sp. mosqui-
toes, aseptic feeding and maintenance of the infected mosquitoes,
and efficient mass extraction of spz from mosquitoes. Most
relevant for our work on Pv spz, we have developed methods for
purification, formulation, vialing, and cryopreservation of spz [20].
We undertook the present pilot study to, (1) assess the feasibility of
producing large quantities of purified, vialed, cryopreserved Pv spz
using the technology platform developed at Sanaria Inc. and (2)
establish a system for culturing the liver stages of Pv in order to assess
the effects of drugs on the liver stages of Pv. We used primaquine (PQ)
to establish this assay model, because PQ is the only licensed drug
known to have an effect on hepatocyte stage development including
clearance of hypnozoites and secondly, unlike with P. berghei [21], P.
cynomolgi and P. knowlesi [22], the effect of PQ has not been evaluated
on Pv hepatocyte stage development in vitro.
Materials and Methods
Pv spz
A chimpanzee at the Yerkes Primate Center, Emory University,
Atlanta, GA was infected with Pv (India VII strain) in order to
have a source of Pv gametocytes. This strain of Pv was earlier
adapted to infect and grow in various new world monkeys and
chimpanzees [23]. Multiple batches of Anopheles dirus mosquitoes
were fed on blood from the infected chimpanzee, and it was
documented at Center for Disease Control & Prevention (CDC),
Atlanta, Georgia that the mosquitoes were infected. The protocol
entitled ‘‘Induction of Plasmodium vivax, P. malariae and P. ovale
infections in chimpanzees to obtain large volumes of parasites for
malaria vaccine studies’’ was approved by the IACUCs at both
CDC and Emory University. All P. vivax infected chimpanzees
were under the supervision of an attending accredited veterinar-
ian, followed twice or thrice weekly by blood smear and treated
with anti-pyretic and anti-malarial medications as determined by
the attending veterinarian to be appropriate to ameliorate fever,
symptoms and to cure the infections. Pv spz-infected mosquitoes
were transported to Sanaria Inc. in Rockville, Maryland under
controlled and secured conditions. At Sanaria, spz were extracted
from infected mosquitoes by dissection of their salivary glands and
passing the glands back and forth through a 26K G needle fitted
to a 1 mL syringe. Following extraction, Pv spz were purified from
mosquito salivary gland material contamination and either used
for infecting HepG2-A16 cells in vitro or vialed and cryopreserved
in liquid nitrogen vapor phase (LNVP).
Immunofluorescence based identity test for Pv spz
Purified Pv spz were suspended in PBS containing 2% bovine
serum albumin (BSA). 10 mL of this suspension, containing 2000
Pv spz was spotted on each of the 12 wells of immunofluorescence
slide (Erie Scientific). Slides were air-dried at room temperature
and stored at 280uC in aluminium foil wraps. A monoclonal
antibody (mAb), NVS3 [24], against the Pv circumsporozoite
protein (PvCSP), was serially two-fold diluted starting at 1:500
(2 mg/mL) using PBS containing 2% BSA. 20 mL of each of the
mAb dilution was added to air-dried spots containing Pv spz and
incubated at 37uC in a humid chamber for 1 hour. Slides were
washed three times, five minutes each, in a glass trough filled with
PBS on a laboratory rocker platform. 20 mL Aleax Fluor 488 Goat
anti-mouse IgG was added to each well of the slides and incubated
for 1 hour at 37uC in a humid chamber. After washing three
times, five minutes each, in a glass trough filled with PBS on a
laboratory rocker platform, slides were mounted with cover slips
using Vectashield mounting medium. Slides were examined with a
fluorescent microscope using a FITC filter.
HepG2-A16 cell culture
Human hepatoma cells, HepG2-A16, were grown in chambers
of 8-well LabTek tissue culture slides (Nunc) using Minimum
Essential Medium (MEM) supplemented with 10% fetal bovine
serum (MEM-10) at 37uC and 5% CO2. In each well of the
LabTek slide 20,000 HepG2-A16 cells were seeded one day before
infection with Pv spz.
Infection of HepG2-A16 cells with Pv spz and
establishment of Pv hepatocyte stage culture
Medium was discarded from the wells of LabTek slides in which
20,000 HepG2-A16 cells were seeded. The cell monolayer in each
well of the LabTek slides was infected with 25,000 Pv spz in 50 mL
MEM-10 medium. Slides were incubated at 37uC and 5% CO2
for 3 hours after which Pv spz suspension was aspirated off from
each well. After three washes with 300 mL MEM-10 medium in
each well each time the slides were incubated with 300 mL MEM-
10 medium in each well at 37uC and 5% CO2 for 3 days with daily
change of medium. Another set of slides with 20,000 HepG2-A16
cells in each well were similarly infected with 50,000 Pv spz and
maintained in culture for nine days with daily change of medium.
Infection rate is defined by the percentage of spz that developed
into liver stage parasites expressing PvCSP.
Infection of HepG2-A16 cells with cryopreserved Pv spz
Vials of Pv spz stored in LNVP were thawed after one year and
were used to infect HepG2-A16 cells as described above. The
cultures were maintained for 3 days with daily change of MEM-10
medium.
Immunofluorescence assay (IFA) to elucidate Pv
hepatocyte stage parasites
On Day 3 and Day 9 post infection with Pv spz, HepG2-A16
cells in LabTek slides were washed three times with sterile PBS,
P. vivax Hepatocyte Drug Assay
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washed again three times with PBS and stored until use with
300 mL PBS in each well at 4uC. Slides from 3 day and 9 day
cultures were incubated at 37uC for 1 hour with 100 mL of the
anti-PvCSP mab, NVS3 (mAb NVS3, 1:50 dilution, 20 mg/mL),
in each well. Some of the 9 day cultures were also stained with
anti-Pv Merozoite Surface Protein-1 (PvMSP-1) ascites, 3F8.A2
(1:50 dilution), which recognizes late stage Pv schizonts in IFA (J.
Barnwell, unpublished) [25]. Secondary conjugate, Alexa Fluor
488 Goat anti-mouse IgG, at 1:200 dilution in PBS containing
0.02% Evans’ blue was added in a 100 mL volume to each well
and further incubated for another hour at 37uC. Wells of the slides
were washed three times, five minutes each, with PBS, at room
temperature on a rocker platform. Slides were mounted with glass
cover slips using Vectashield (Hard set) and stored at 4uC
overnight. Slides were observed under UV in a fluorescent
microscope using FITC filter and the number of hepatocyte stage
parasites present in the entire area of each well was counted. The
following formula was used to calculate the rate of infection of Pv
spz in HepG2-A16 cells- [Mean of number of hepatocyte stage
parasites in well/Number of Pv spz added in the well]6100.
Primaquine (PQ) treatment of Pv hepatocyte stage
parasites cultured in HepG2-A16 cells in vitro
Establishment of the cell culture for PQ treatment was identical
to that described above for 3 day and 9 day cultures of Pv
hepatocyte stages. Pv spz were incubated with HepG2-A16 cells
for 3 hours. After 3 hours the wells were washed to remove Pv spz
in suspension. At that time PQ was diluted from the stock to five
10-fold dilutions from 10.0 mg/mL to 0.001 mg/mL in MEM-10
medium and 300 mL of each dilution was added to triplicate wells.
Everyday fresh drug dilutions were prepared in MEM-10 medium
and added to the culture. 3 and 9 days post infection of cells with
Pv spz and initiation of PQ treatment fixation of cells in chilled
methanol followed by labeling with mAb NVS3 was performed as
described above for the IFA. The number of hepatocyte stage
Figure 1. Immunofluorescence Assay. Air dried Pv spz were
immunostained with monoclonal antibody against PvCSP (NVS3) at
0.98 ng/mL as described in Materials and Methods. The end point titer
is 1:1,024,000.
doi:10.1371/journal.pone.0014275.g001
Figure 2. In-vitro development of liver stage parasites. 25,000 Pv
spz was used to infect 20,000 HepG2-A16 cells. Uninfected spz were
washed off after three hrs and cells were maintained for 3 days with
daily media change. Cells were fixed and Pv liver stage trophozoites
(400 X magnification) were stained with mAb NVS3 against the PvCSP
(20 mg/ml). N: Nucleus of HepG2-A16 cells, C: Cytoplasm of HepG2-A16
cells, P: Developing 3 day old Pv hepatocyte stage parasite
(trophozoite).
doi:10.1371/journal.pone.0014275.g002
Figure 3. Multiple Pv liver stage parasites were seen in single
hepatocyte in a 3 Day culture. HepG2-A16 cells were infected with
Pv spz and the liver stage trophozoites were stained with the anti-
PvCSP mAb, NVS3. Some HepG2-A16 cells were seen with multiple liver
stage parasites (400X magnification). N: Nucleus of hepatocyte, C:
Cytoplasm of hepatocyte, White Arrows: Individual 3 Day hepatocyte
stage Pv.
doi:10.1371/journal.pone.0014275.g003
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under fluorescent microscope and the percentage reduction in
parasite load in the hepatocytes after 3 days and 9 days of PQ
treatment post infection was calculated as- [(MMedium Control Wells
2 MPQ treated Wells)/MMedium Control Wells]6100; M= Mean
number of hepatocyte stage parasites.
Results
Pv (India VII strain) spz harvest from infected mosquitoes
627 A. dirus mosquitoes were processed to harvest spz from their
salivary glands. 23.9610
6 purified, Pv spz were isolated. A part of
this Pv spz harvest was used for setting up assays with HepG2-A16
hepatocytes and part was vialed and cryopreserved in LNVP.
Pv spz identity test
An immunofluorescence assay (IFA) using the mAb NVS3
(1 mg/mL) confirmed the identity of the spz as being Pv (Figure 1),
because NVS3 mAb reacts exclusively against Pv CSP. Pv spz
were found to react with this mAb at a very high dilution,
1:1,024,000 (0.98 ng/mL).
Development of hepatocyte stage parasites in Pv spz
infected HepG2-A16 cells
25,000 Pv spz were added to 20,000 HepG2-A16 cells in each
well, and cultured for 3 days and 50,000 Pv spz were added to
20,000 hepatoma cells in each well, and cultured for 9 days.
Figure 2 shows a 3-day-old hepatocyte stage trophozoite of Pv,
which reacted strongly with the anti-PvCSP mAb, NVS3,
Infection of a single hepatocyte with multiple Pv spz and their
subsequent development within the single hepatocyte was also
observed (Figure 3). Nine days after infection of HepG2-A16
hepatocytes with Pv spz, large, hepatocyte stage parasites were
visible which reacted with mAb NVS3 (figure 4A). These 9 day old
parasites also reacted with the anti-PvMSP-1 mAb, 3F8.A2 and
developing merozoites in infected hepatocytes were visible
(Figure 4B), as has been previously shown with the same mAb
[25]. In 9-day cultures, some parasites (generally less than 10%), as
small as the parasites seen in the 3 day culture, were also observed
to react strongly with the NVS3 mAb (Figure 5). It is possible that
these small parasites observed in the 9 day culture were
hypnozoites, which did not grow at the same rate as did the
parasites that developed to mature late stage hepatocyte stage
parasites. The results of a single experiment are shown in Table 1.
In the 3-day assay a mean of 458 parasites were identified per well
indicating that 1.8% of the 25,000 spz that were added to the well,
invaded and developed. In the 9 day assay a mean of 493 parasites
(large and small forms) were identified per well indicating that
0.9% of the 50,000 spz that were added to the well, invaded and
developed, and stayed identifiable through 9 days of culture.
Development of hepatocyte stage parasites in infected
HepG2-A16 cells from Pv spz cryopreserved for one year
When Pv spz stored in LNVP for one year were used to infect
HepG2-A16 cells, they were found to retain their capacity to invade
hepatocytes and transform into hepatocyte stage parasites similar to
fresh Pv spz. In a 3-day assay, the percent infection rate with fresh
Figure 4. In-vitro development of late liver stage schizonts expressing PvMSP1. 20,000 HepG2-A16 cells were infected with 50,000 Pv spz.
Three hrs later uninfected Pv spz were washed off and the culture was maintained for 9 days with daily media changes. Mature Pv liver stage
schizonts (400 X magnification) in HepG2-A16 cells were stained with (A) the mAb to the PvCSP, NVS3 (20 mg/ml) or (B) with a mAb against Pv
merozoite surface protein 1(PvMSP1), 3F8.A2 (1:50 dilution). As a negative control, uninfected HepG2-A16 cells were incubated with the individual
mAbs and labeled secondary antibodies. There was no evidence of staining in these negative control cultures (data not shown).
doi:10.1371/journal.pone.0014275.g004
Figure 5. Are these hypnozoites? HepG2-A16 cells were infected,
maintained for 9 days as described in Fig 4 and stained with PvCSP
mAb. Approximately 10% of the Pv liver stage parasites that expressed
PvCSP were similar in size to 3-day trophozoites, and much smaller than
the 9-day schizonts. Are these hypnozoites?
doi:10.1371/journal.pone.0014275.g005
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cryopreserved Pv spz from the same lot was 1.95% (Table 2).
Effect of PQ treatment on hepatocyte stage parasites of
Pv in vitro
Pv spz were added to wells containing 20,000 hepatoma cells and
cultured for 3 or 9 days. Primaquine (PQ) at 5 different
concentrations was added to the wells. The old medium and drug
were removed daily and new medium and PQ were added. At the
end of the experiment (3 or 9 days) the cells were fixed and the
numbers of early liver stage trophozoites (3 day assay) or late liver
stage schizonts (9 day assay) were counted by immunofluorescence
microscopy after staining with mAb NVS3. Figure 3 (3 day assay)
shows a maximum of 40% of reduction in early hepatocyte stage
(trophozoites) at 10 ug/mL of PQ whereas Figure 4 (9 day assay)
demonstrates a dose response effect of PQ on the development of Pv
late hepatocyte stage (schizont) in HepG2-A16 cells. The resulting
50% effective concentration (EC50) of PQ after 9 days was between
1 and 0.1 mg/ml. There was no toxicity to the HepG2-A16 cells at
any concentration from 0.001 mg/ml to 10 mg/ml in the 3-day
assay, and no toxicity to the HepG2-A16 cells at concentrations
from 0.001 mg/ml to1 mg/ml inthe9-dayassay.However,inthe 9-
day assay at the highest dose of PQ (10 mg/mL), significant
cytotoxicity of non-infected hepatocytes was observed as marked by
focal loss of cells from the culture wells and presence of dense bodies
in the cytoplasm of cells (Figure 6). Since the 50% effective
concentration (EC50) of PQ in this assay was between 0.1 mg/ml
and 1 mg/ml, the assay can still be used to demonstrate the effect of
PQ on Pv liver stage development. Furthermore, we have
subsequently identified a lot of PQ that has the same activity
against Pv parasites, but does not have toxicity against the HepG2
cells at 10 mg/mL (Velmurugan S, unpublished).
Discussion
The goal of malaria eradication [26] cannot be realized without
adequate interventions to eliminate infections by all species of
malaria parasites that infect humans. Pv causes much less severe
disease and death than does P. falciparum, but is more widespread
globally and infects 80–300 million people every year [3]. Unlike
the other major human malaria parasite, P. falciparum, there is no in
vitro cultivation system to produce Pv asexual and sexual
erythrocytic stage parasites. Also, like P. falciparum there is no
small animal model available for Pv. These deficiencies undermine
efforts to develop drugs and vaccines against Pv, especially against
the pre-erythrocytic stages. Elimination of Pv would be facilitated
by development of an easily administered drug that eliminates all
liver stage parasites, including hypnozoites, and can be given to
the entire population in mass treatment campaigns without
concern for life threatening side effects. Identification and
development of such a drug would be facilitated by an in vitro
screening assay.
Herein, we report the first steps toward development of a
medium throughput and high content assay to screen for new
drugs against Pv liver stages. One of the serious problems with
developing such an assay is that it has been extremely difficult to
acquire Pv spz for such studies, and that each time a study is done,
the study has to be done with spz from a different infection and/or
source. This of course limits the capacity to do multiple, reliable
comparisons. For the first time we report that cryopreserved Pv
spz from the same lot can be used to reproducibly infect hepatoma
cells, and that the numbers of 3 day hepatocyte stage parasites are
similar in cultures infected with fresh and cryopreserved Pv spz
(Table 2). Similar results have now been obtained with
cryopreserved Pv spz in the 9 day assay (Velmurugan, S,
manuscript in preparation). Being able to produce and vial large
single lots of Pv spz that can be used in multiple experiments over
time is a first prerequisite to developing a medium to high
throughput screening assay.
The next step is to make the assay reproducibly quantitative.
The earlier reports on culturing Pv liver stages [17,18] provided
primarily qualitative data that described the ability of primary
human hepatocytes or human hepatocyte lines to support the
development of hepatocyte stages of Pv and the morphology of
Table 1. In vitro development of hepatocyte stage parasites.
Days in Culture Pv hepatocyte stage Parasites/Well Infection rate (%)
Well 1 Well 2 Well 3 Mean STDEV
3 461 486 465 457.66 30.14 1.8
9 426 521 492 492.67 28.01 0.9
25,000 Pv spz were added to wells containing 20,000 hepatoma cells and were cultured for 3 days and 50,000 Pv spz were added to wells containing 20,000 hepatoma
cells and were cultured for 9 days, and the numbers of early liver stage trophozoites (3 day assay) or late liver stage schizonts (9 day assay) were counted by
immunofluorescence microscopy after staining with the anti-PvCSP mAb, NVS3 (20 mg/mL).
doi:10.1371/journal.pone.0014275.t001
Table 2. No change in infectivity after cryopreservation of Pv spz.
Date of the Assay Pv spz Used Pv Hepatocyte Stage Parasites/Well Infection Rate (%)
Well 1 Well 2 Well 3 Mean STDEV
Nov 2007 Cryo-preserved 466 510 489 488.3 22.01 1.95
Nov 2006 Fresh 510 439 461 470.0 36.35 1.88
25,000 Pv spz (Fresh or thawed after cryopreserved in LNVP for one year) were added to wells containing 20,000 hepatoma cells and cultured for 3 days. The numbers of
early liver stage trophozoites (3 day assay) were counted by immunofluorescence microscopy after staining with the anti-PvCSP mAb, NVS3, as described in Materials
and Methods.
doi:10.1371/journal.pone.0014275.t002
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rate of infectivity of Pv spz in HepG2-A16 cells and rate of
development of invaded Pv spz into hepatocyte stages. We
observed that when 25,000 Pv spz were added to 20,000 HepG2-
A16 cells and the culture was maintained for 3 days, the overall
rate of infectivity was 1.8%, and this was reduced by about 50% to
0.9% when the cultures were maintained for 9 days (Table 1). Our
data with Pf spz cultured in HC-04 cells (Chakravarty, S,
unpublished), as well as Pv spz cultured in HepG2 cells
(Velmurugan, S, unpublished) indicate that about 50% of the
spz added to the wells at the outset of the culture are washed out
3 hours later. Thus, of the spz remaining, the overall infectivity is
double that which we record for both the 3 and 9 day assays. We
think that the difference in numbers of parasites between 3 and 9
day assays is attributable to 1) the fact that some of the 3 day
parasites do not fully develop, 2) hepatoma cell death during the
period from 3 to 9 days, including cells containing parasites, and 3)
replication of the uninfected hepatoma cells in the wells, which
makes it more difficult to visualize parasites after 9 days. The
infectivity of Pv spz in the HC-04 human hepatocyte line is
reported to be 0.041% [19]. HepG2-A16 and HC-04 hepatocyte
lines differ biologically, but both of them support development of
hepatocyte stages of Pv. The difference in the results from
Thailand with HC-04 cells [19] and our results in regard to rate of
infectivity in these two lines could be due to the inherent capacity
for infection of the two cell lines. However, other factors could
have been responsible for the different infectivity rates. We used a
single strain (India VII), which has been maintained at CDC since
2001 [23] and fed mosquitoes on infected chimpanzee blood. The
Thai group used Pv spz produced from gametocytes infecting
people in the field. Another potential factor may be that the
purified Pv spz that we use may be associated with higher infection
rates, as compared to the unpurified Pv spz used by all other
groups. In unpurified Pv spz preparations there may be
contaminant molecules of mosquito origin, which compete with
Pv spz to bind to the hepatocytes, but purification of Pv spz from
these mosquito components might allow Pv spz to attach to and
invade hepatocytes more efficiently and at higher rate.
Next we showed, for the first time, that our hepatocyte stage
culture system could be used to assess drugs against Pv liver stages
in vitro. There was a clear dose response when using PQ (Table 3
and 4). Most data suggest that the primary activity in vivo when PQ
is used to eliminate infected hepatocytes is by a metabolite of
primaquine, not by the parent compound. This is probably the
reason why such large quantities of primaquine (EC50 of 0.1 to
1.0 mg/mL) were required, even for the 9-day assay. Work is in
progress in an attempt to isolate the active metabolites of
primaquine (Colin Ohrt, personal communication) and we
anticipate assessing its activity in the future.
In the 9-day assay 10 mg/mL inhibited parasite development by
86% while in the 3-day assay there was only a 36% reduction at
10 mg/mL. The total cumulative dose of PQ is important for
complete elimination of liver stages of Pv in vivo [15,27]. The
greater effect of PQ observed in the 9-day assay as compared to
the 3-day assay may have been due to the cumulative effect of PQ
Figure 6. Hepatotoxic changes in HepG2-A16 cells after
treatment with high dose primaquine for 9 days. Culturing
HepG2-A16 cells with high concentrations of primaquine (10 mg/mL)
induced hepatotoxic changes. P: Parasite; White arrows: Dense bodies
in cytoplasm; E: Empty spaces due to focal cell loss in the cell culture
well.
doi:10.1371/journal.pone.0014275.g006
Table 3. Dose dependent effect of primaquine on the development of 3 day hepatocyte stage parasites.
PQ Dose (mg/mL) Pv Hepatocyte Stage Parasites/Well Reduction in Liver stage Parasites (%)
Well 1 Well 2 Well 3 Mean SD
0.0 461 426 486 457.67 30.14 -
0.001 458 423 485 455.33 31.09 0.51
0.01 431 448 476 451.67 22.72 1.30
0.1 412 443 408 421.00 19.16 8.01
1.0 401 363 349 371.00 26.91 18.93
10.0 291 276 312 293.00 18.08 35.97
25,000 fresh Pv spz were added to wells containing 20,000 hepatoma cells and were cultured for 3 days with medium alone or in the presence of different
concentrations of primaquine (PQ). The numbers of early liver stage trophozoites (3 day assay) were counted by immunoflourescence microscopy after staining with the
anti-PvCSP mAb (NVS3) as described in Materials and Methods.
doi:10.1371/journal.pone.0014275.t003
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the kinetics of activity of PQ and other drugs by looking at the
results after 3 to 9 days of treatment. At 10 mg/mL for 9 days,
hepatotoxicity was observed, as has been seen in cultures of P.
cynomolgi and P. knowlesi hepatocyte stages in primary rhesus
monkey hepatocytes [22]. This would be a limiting variable in
these cultures. However, subsequent work with a different lot of
primaquine has shown much less cytotoxicity (Velmurugan, S,
unpublished).
An ideal drug for elimination of Pv will be effective against
hypnozoites. Hypnozoites or dormant hepatocyte stages of Pv
were observed in vivo and possibly in HepG2-A16 cells after
infection with Pv spz [9,18,28]. Identifying and characterizing
hypnozoites is a major emphasis of our research program. Thus,
the small forms expressing PvCSP that we have identified in the 9-
day cultures intrigue us. Much work will be needed to determine if
these are truly hypnozoites.
We have established the capacity to reproducibly infect
hepatoma cells with Pv spz, quantitate the primary outcome
variable of infected hepatoma cells and demonstrate the inhibitory
activity of primaquine on the infected hepatoma cells. We have
also identified small parasite forms that may be hypnozoites. We
are now moving to a 96-well format that will use less Pv spz/well
and less time to quantitate infected hepatocytes, automated read
outs, establishment of the effect of other drugs on the cultures and
characterization of the small forms. With these improvements, we
anticipate a medium throughput assay can be developed in near
future that can be used to screen for new drugs against Pv
hepatocyte stages.
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